Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN- β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in p atients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. (Source: Journal of Neuroimmunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SVsImv